How to Qualify Diglucosyl Gallic Acid When Supplier Identity Fields Conflict

Quick Answer

Do not approve Diglucosyl Gallic Acid because a listing says 97%, 98% or 99%. First reconcile the material identity, CAS number, INCI name, product code, assay basis and batch documentation. This matters because current commercial pages do not present a consistent CAS field: some list 1782069-25-3, while another bulk page lists 131707-40-7. That discrepancy is not, by itself, proof that a supplier is fraudulent. It is a reason to stop, ask for the supplier's controlled identity statement, and check whether the document refers to the same molecule, a branded active, a premix or free gallic acid.

What a Buyer Is Actually Qualifying

Diglucosyl Gallic Acid is a glycosylated gallic-acid derivative listed as a distinct chemical substance in PubChem (CID 11504173). In a purchasing file, however, the name can sit next to several different commercial descriptions: gallic acid glucoside, trihydroxybenzoic acid glucoside, THBG, a branded active such as Brightenyl, or simply gallic acid. These labels are not interchangeable without a composition and identity check.

The first distinction is between the molecule and the commercial material. A defined small-molecule powder should have an identity and assay package that describes the named substance. A branded active may have its own trade name, carrier, recommended use level and clinical dossier. A plant extract may report gallic acid or total polyphenols without containing Diglucosyl Gallic Acid as the declared principal substance. If those three are mixed in a quotation, price comparison becomes meaningless.

The second distinction is between evidence for the ingredient and evidence for a finished formula. A study may test a lotion, an emulsion or a multi-active system. Its result cannot automatically be converted into a release specification for every powder sold under a similar name.

Why the CAS Field Deserves a Stop-and-Check

A Canada.ca chemical-substance record identifies Diglucosyl Gallic Acid with CAS 1782069-25-3. PubChem also provides a structure record for the named compound. At the same time, a current commercial bulk listing reviewed for this article displays CAS 131707-40-7 for Diglucosyl Gallic Acid. Because commercial pages can contain copied or supplier-entered metadata, the correct buyer response is not to choose whichever number appears more often. Ask the supplier to explain the relationship between the CAS number, the structure, the INCI name and the batch test method.

Request a signed identity statement on company letterhead or in the controlled TDS/COA package. It should state whether the material is the neat compound, a solution, a carrier-containing active or an extract. It should also show the exact product code and revision date. If the supplier cannot explain the discrepancy, keep the offer in technical hold even if the price and purity look attractive.

Read the COA as a Chain of Evidence

A COA is useful only when the line items connect to the material you are buying. A high assay number without a clear method can be less informative than a lower but well-defined specification. Review the document in this order:

For this ingredient, 98% needs a definition. It may mean chromatographic area percentage for the target peak, an assay against a reference standard, or a supplier's internal calculation. Ask for the method, reference standard, sample preparation, chromatogram and specification limits. If the supplier will not provide the method, write supplier-declared assay; method not independently reviewed in the comparison sheet rather than presenting it as a verified purity fact.

Use Orthogonal Identity Evidence

A practical identity package should not rely on one copied PDF. For a first qualification, request at least the following:

• A current, batch-specific COA with product code, lot number, manufacture date, retest or expiry date and authorized sign-off.
• A TDS stating the material form, expected appearance, solubility, storage conditions and whether any carrier or preservative is present.
• An identity method that can distinguish Diglucosyl Gallic Acid from free gallic acid and other gallic-acid glycosides. LC-MS, NMR or a validated chromatographic identity test may be appropriate depending on the supplier's quality system.
• A chromatogram or representative analytical package when the assay is the main commercial differentiator.
• A process and change-control statement identifying whether the product is enzymatically produced, chemically processed or derived from an extract. The method does not need to be disclosed in proprietary detail, but the material description must remain truthful.

The 2017 research paper on transglycosylation of gallic acid is useful background because it describes enzymatic synthesis and characterization of a gallic-acid glucoside. It is not a universal supplier specification. A supplier may use another route, another purification scheme or a carrier. The paper therefore supports the need for structural and chromatographic confirmation, not a claim that every commercial powder has the same impurity profile.

Questions to Put in the First RFQ

A short, consistent RFQ prevents suppliers from answering different questions with different definitions of purity. Ask each candidate to reply against the same fields:

• Exact product name, INCI name, CAS number, molecular formula and supplier product code.
• Neat active or blended commercial material; if blended, every carrier or solvent and the active-equivalent percentage.
• Manufacturing route at a high level, country of manufacture and whether the quoted material is made in the same site shown on the company profile.
• Assay method, reference standard, acceptance range and whether the result is reported on an as-is or dry basis.
• Identity data available for the offered grade, including chromatogram, LC-MS, NMR or an equivalent controlled method.
• Batch size, sample lot, MOQ, packaging, storage, retest period and change-notification policy.
• Available microbial, heavy-metal, residual-solvent, allergen and regional compliance documents relevant to the buyer's market.

The purpose is not to force every supplier to disclose proprietary synthesis details. It is to make the commercial offer auditable. A supplier who answers clearly can still be screened out for price, capacity or formulation fit. A supplier who will not identify the material clearly should not be ranked as a low-cost alternative; it should remain an unresolved technical risk.

Keep Cosmetic Evidence in Its Proper Lane

A 2022 International Journal of Cosmetic Science paper evaluated diglucosyl gallic acid in antioxidant, tyrosinase-related and cosmetic-application work, including a small volunteer experiment using a lotion. The study is relevant to ingredient rationale, but the tested emulsion, dose, controls and study conditions are part of the evidence. They do not establish that any powder labeled Diglucosyl Gallic Acid 98% will reproduce the same result in a different formula.

A separate paper on a depigmentation formula used Diglucosyl Gallic Acid as one factor among several actives in a designed mixture. That type of work can inform formulation screening, but it is not a raw-material identity test. It also illustrates why a buyer should not copy a supplier's finished-product claim into a COA or purchasing specification.

The most defensible commercial language is therefore conditional: the ingredient has published cosmetic-research support for antioxidant and pigmentation-related investigation, while finished-product performance remains dependent on identity, concentration, vehicle, stability, skin model or study design, and the rest of the formula. Avoid clinically proven unless the supplier can provide the complete study and the tested material can be shown to match the offered batch.

Do Not Hide the Formulation Risk Inside the Raw-Material Name

Check Whether the Offer Is Neat Powder or an Active System

Some brightening ingredients are sold as named actives with a carrier, solvent or standardized blend. If the supplier presents a branded active or a solution beside a powder listing, ask for the active-equivalent calculation. A 1% use level for a 20% active solution is not equivalent to 1% of a neat powder. The label, INCI declaration, preservative system, water content and microbial risk can all change.

For a neat powder, clarify particle form, hygroscopicity, packaging barrier and storage. For a liquid or carrier system, clarify solvent, solids, preservative, density, pH and freeze-thaw or transport limits. Do not compare a low-priced extract or premix with a high-priced defined active on a dollar-per-kilogram basis alone.

Diglucosyl Gallic Acid is water-compatible in the research and supplier descriptions reviewed, but that does not remove ordinary formulation work. A clear solution can become colored or hazy after heat, light, pH adjustment, preservative addition or interaction with other actives. Solubility claims should therefore be checked in the actual vehicle, at the intended concentration and after a realistic hold period.

For development samples, record the lot, addition order, temperature, pH, appearance and assay if the material is central to the product claim. If the final formula uses a branded active rather than a neat powder, record the active-equivalent dose and the supplier's recommended handling conditions separately. This keeps a formulation observation from being misread as a universal property of the molecule.

A Buyer-Side Qualification Sequence

1. Define the intended material in one line: Diglucosyl Gallic Acid, defined powder, no undisclosed carrier, cosmetic raw-material use.
2. Send the same identity and documentation request to each supplier before discussing a final price.
3. Reconcile CAS, INCI, product code, assay basis and physical form across the quotation, TDS, SDS, COA and sample label.
4. Review the batch COA and request an identity package if the CAS or name is inconsistent.
5. Run a small formulation screen for solubility, color, pH compatibility, preservation and short-term stability in the intended base.
6. Approve the supplier only after the sample, documents and commercial material are demonstrably linked by lot and product code.

This sequence is deliberately slower than selecting the highest percentage on a marketplace page. It is faster than discovering after scale-up that the delivered material was a different gallic-acid derivative, a carrier system or an extract with a non-comparable assay.

A Simple Rejection Rule

Reject or suspend the offer when the supplier cannot link the sample to the COA lot; when the CAS conflict is ignored rather than explained; when purity has no defined method; when the product name changes between the quotation and the documents; or when the supplier presents a finished-product or branded-active study as proof of neat-powder equivalence. These are documentation failures, not conclusions about the supplier's character. The file can be reopened if the missing evidence is supplied and matches the material.

Current Alibaba Sourcing Lead and sourcing link Status

A current Alibaba search surfaced a direct product page titled Wholesale Diglucosyl Gallic Acid Brightening Material, product ID 1601052535073. Search metadata describes a 98% material and associates the offer with Xi'an Ebos Biotech Co., Ltd. The product and supplier link destinations below were provided and verified by the buyer for this article. This commercial verification does not replace technical approval: the current documentation, CAS field and batch COA still require buyer-side review before any purchase decision.

These links are commercial verification results, not technical qualifications. Before publication or ordering, verify the raw product page, product sourcing option redirect, supplier redirect, Product ID, supplier identity and current document set together.

Final Rule

For Diglucosyl Gallic Acid, the first purchasing question is not What purity can you quote? It is Can you prove that the named material, the CAS field, the assay method, the sample and the batch COA all describe the same thing? Until that chain is intact, the offer belongs in technical hold. Once it is intact, formulation testing and commercial comparison become meaningful.

References

1. National Center for Biotechnology Information. PubChem Compound Summary: Diglucosyl Gallic Acid, CID 11504173. https://pubchem.ncbi.nlm.nih.gov/compound/11504173
2. Health Canada. Chemical Substance: Diglucosyl Gallic Acid; CAS registry number 1782069-25-3. https://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq?id=17055
3. Zhang Y, et al. Research on antioxidant performance of diglucosyl gallic acid and its application in emulsion cosmetics. International Journal of Cosmetic Science). 2022;44(2):177-188. https://pubmed.ncbi.nlm.nih.gov/35211990/
4. Kang S, et al. Transglycosylation of gallic acid by Leuconostoc glucansucrase and characterization of the product as a cosmetic agent. Journal of Agricultural and Food Chemistry. 2018. https://pubmed.ncbi.nlm.nih.gov/29273963/
5. Huang Y, et al. Trihydroxybenzoic acid glucoside as a global skin color modulator and photo-protectant. International Journal of Cosmetic Science. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4664441/
6. Optimizing a Skin Depigmentation Formula Using a 2^4 Factorial Design: Evaluating 4-n-Butylresorcinol, Undecylenoyl Phenylalanine, Diglucosyl Gallic Acid and trans-Resveratrol. https://pmc.ncbi.nlm.nih.gov/articles/PMC12573049/